Safety Profile of 5-Aminolevulinic Acid as a Surgical Adjunct in Clinical Practice
Authors:
- Antonio Martinez-SimónAMAntonio Martinez-Simón
- Elena Cacho-AsenjoECElena Cacho-Asenjo
- Francisco Guillén-GrimaFGFrancisco Guillén-Grima
- Sonia Tejada-SolísSTSonia Tejada-Solís
- Ricardo Diez-ValleRDRicardo Diez-Valle
- 1 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 27 (4) , 304-309
Abstract
5-Aminolevulinic acid (5-ALA) is used for brain tumor identification during surgery through fluorescence. Its use is linked to side effects such as photodermatosis, anemia, or plaquetopenia. Many institutions take very strict precautions to prevent them. Our hospital's protocol mandates avoidance of direct sunlight during the first 24 hours only. Retrospective cohort observational study of 207 consecutive patients who underwent 5-ALA-guided brain tumor resection between 2008 and 2013, and compared with a control group of 53 patients without 5-ALA. No skin reaction was reported. No difference was found in hemoglobin or platelet level comparisons at different points in time. There was no difference in trends within groups. Mean duration of surgery was longer in the 5-ALA group; the subgroup of patients undergoing their first surgery had a positive correlation with lower hemoglobin levels. In postoperative magnetic resonance imaging, patients in the 5-ALA group had a lower percentage of residual bleeding (19% of all patients; 17.9% in 5-ALA group and 22.7% in non-ALA [P=0.04]). Eight patients in the 5-ALA group required blood transfusion (3.9%), compared with 2 in the control group (3.8%). Four patients in the 5-ALA group required reintervention in the first 48 hours due to bleeding, although none had platelets <150,000/mL. Significant side effects appear to be uncommon. Blood count changes are likely multifactorial; surgical time may account for it partially, whereas 5-ALA role is not clear and may not be significant.Keywords
This publication has 20 references indexed in Scilit:
- Intraoperative Fluorescence-Guided Resection of High-Grade Gliomas: A Comparison of the Present Techniques and Evolution of Future StrategiesWorld Neurosurgery, 2014
- Estudio observacional retrospectivo sobre la efectividad del ácido 5-aminolevulínico en la cirugía de los gliomas malignos en España (Estudio VISIONA)Neurología, 2014
- Risk factors for developing oral 5-aminolevulenic acid-induced side effects in patients undergoing fluorescence guided resectionPhotodiagnosis and Photodynamic Therapy, 2013
- Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoringJournal of Neurosurgery, 2010
- Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomasActa Neurochirurgica, 2010
- ALA and its clinical impact, from bench to bedsidePhotochemical & Photobiological Sciences, 2007
- ALA and Photofrin® Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trialLasers in Medical Science, 2007
- Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5‐aminolevulinic acid induced protoporphyrin IXLasers in Surgery and Medicine, 2007
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patientsJournal of Neurosurgery, 2000